Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
74.4M
-
Number of holders
-
58
-
Total 13F shares, excl. options
-
27.7M
-
Shares change
-
-495K
-
Total reported value, excl. options
-
$66.7M
-
Value change
-
-$7.83M
-
Put/Call ratio
-
1.08
-
Number of buys
-
33
-
Number of sells
-
-26
-
Price
-
$2.41
Significant Holders of Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) as of Q4 2021
83 filings reported holding CRVS - Corvus Pharmaceuticals, Inc. - Common Stock as of Q4 2021.
Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) has 58 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 27.7M shares
of 74.4M outstanding shares and own 37.22% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (6.94M shares), ADAMS STREET PARTNERS LLC (3.28M shares), TANG CAPITAL MANAGEMENT LLC (3.1M shares), MILLENNIUM MANAGEMENT LLC (2.92M shares), BVF INC/IL (1.37M shares), VANGUARD GROUP INC (1.23M shares), RENAISSANCE TECHNOLOGIES LLC (1.04M shares), TWO SIGMA INVESTMENTS, LP (930K shares), Point72 Asset Management, L.P. (795K shares), and TWO SIGMA ADVISERS, LP (763K shares).
This table shows the top 58 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.